People  |  News  |

Manufacturing advanced therapies in Europe

Manufacturing advanced therapies in Europe

A comprehensive guide to Europe's growing advanced therapies and viral vector manufacturing landscape

The new Italian industrial complex entirely dedicated to the development and production of cell and gene therapies is called EXELLULA and it will be a world centre of excellence for nonviral technologies.

There is no doubt about the strength of the pipeline of advanced therapy products, with more approvals predicted in Europe in 2019 and beyond.

However, ensuring sufficient manufacturing capacity across the region and a robust infrastructure to deliver therapies at scale and where they’re needed are absolutely crucial to successful commercialisation of these advanced therapies and those already on the market.
Where and who are the leading CMOs and viral vector manufacturers in Europe?More importantly what are their capabilities and specialities? Can they manufacture at commercial scale? Who’s the best partner?
This map is a tool for you to review the capacities, locations and specialist services of over 15 of Europe’s leading CMOs and viral vector manufacturers. It’s interactive too, so look out for the + while you explore!

Take a look at the other regional CMO maps below:

1200 600 Anemocyte

Anemocyte S.p.A Single Shareholder Private Limited-Liability Company
Via R. Lepetit, 34 21040 Gerenzano (VA) Italy | Ph: +39 02 99372311 – Fax: +39 02 99372313 | VAT number: 12914940155 | Share capital € 530.000,00 fully paid | R.E.A. 276961